Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novo Nordisk

Novo Nordisk Foundation CEO dismisses ‘Nokia risk’ to Denmark’s economy

Novo Nordisk Foundation CEO Mads Krogsgaard Thomsen said only 9 million people are using GLP-1s compared with 1 billion people living with obesity.

Fortune

Wegovy on sale in China, cheaper than US

The medication is currently available in 16 other countries

Salon

Weight-Loss Drugmakers Press Companies To Cover Cost Of Treatment

The efforts by Eli Lilly and Novo Nordisk could be a game-changer for sales, which some analysts say could exceed $100 billion a year.

International Business Times

From analysis to the latest developments in health,
read the most diverse news in one place.

Buy This Pharma Stock to Bet on the Next Blockbuster Weight-Loss Drug

A shocking study in The Lancet showed that nearly three-quarters of U.S. adults are overweight or obese. Chances are that by 2050, there will be 260 million overweight Americans. We already have GLP-1 drugs, and amylin-based drugs are next. Novo Nordisk's compound, Cagrilintide, will be combined with semaglutide in its…

Barchart

Drugmakers see stocks tank after RFK Jr is nominated to oversee health department

JP Morgan Chase analysts say they’re ‘not surprised’ sector has come ‘under pressure’ since Kennedy’s nomination

The Independent UK

Obesity Drug Maker Novo Nordisk Posts Strong Profit

Danish pharmaceutical giant Novo Nordisk, maker of the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, posted Wednesday strong third-quarter earnings despite being held back by production constraints.

International Business Times

Danish town where Ozempic is made has highest rates of overweight children in Denmark

Novo Nordisk faces a challenge turning around the fortunes of residents in a major Danish manufacturing hub.

Fortune

Read news from The Economist, FT, and more,
with one subscription

Thanks to Wall Street, Novo Nordisk Stock is Now a Buy

Novo Nordisk has lost about a quarter of its value since the end of June. Meanwhile, indications are that its diabetes and weight-loss drugs may be useful in fighting cardiovascular disease, arthritis, opioid and alcohol addiction, and Alzheimer's. Novo remains a leader in the sector, and is trading at a…

Barchart

Weight loss drugs may cause addiction switching, says award-winning therapist

Labour’s plans to give weight loss drugs to the unemployed may not just fail: it could backfire, therapist Sally Baker explains

Evening Standard

Ozempic, Wegovy considered ‘available’ after more than 2 years in shortage

Demand for the popular weight loss and diabetes drugs has spiked dramatically in recent years

The Independent UK

Ozempic, Wegovy or Mounjaro? The battle of the weight-loss injections

As drugs emerge as vital to the Government’s anti-obesity strategy, BBC Panorama is shedding light on the pharmaceuticals industry behind them

Evening Standard

Pumping the unemployed with weight-loss drugs echoes Victorian attitudes to the poor

Shifting blame to the victims of economic policy is an old trick by politicians. Now they’re using obesity to tackle joblessness

The Guardian - UK

Declan Irvine uses 'pioneer' eating skills to manage diabetes and battle Life Time Grand Prix riders at Big Sugar Gravel

Team Novo Nordisk rider among a trio of top Australians in elite men's field

Cycling News

Weight-loss drug firm accused of prioritising profits after halting insulin pen production

Novo Nordisk’s decision will force people in developing countries to use outdated glass vials and syringes, warn campaigners

The Guardian - UK

Get all your
news in one place.

100’s of premium titles.
One news app.

The Conversation

Glucose monitors for diabetes have finally been funded – but a chronic workforce shortage will limit the benefits

Pharmac’s decision to fund continuous glucose monitors and automated insulin delivery systems for the approximately 18,000 people who currently live with type 1 diabetes in Aotearoa New Zealand is good news.

Fortune

Here are the facts that activist critics of Pfizer CEO Albert Bourla are missing, according to a Yale analysis

'Some misleading narratives about Bourla’s leadership that have been put forward have been distinctly unfair,' write Jeff Sonnenfeld and Steven Tian.

The Conversation

Buyer beware: Off-brand Ozempic, Zepbound and other weight loss products carry undisclosed risks for consumers

In just a few years, brand-name injectable drugs such as Ozempic, Wegovy, Mounjaro and Zepbound have rocketed to fame as billion-dollar annual sellers for weight loss as well as to control blood sugar levels and reduce the risk of heart disease.

Barchart

This Weight-Loss Stock Just Scored a New Street-High Price Target

Down 43% from all-time highs, Structure Therapeutics is a pre-revenue clinical-stage biopharma company that trades at a massive discount to consensus price target estimates.

Get all your
news in one place.

100’s of premium titles.
One news app.

inkl

Failure to Warn: The Type of Product Liability Ozempic is Being Sued for

Ozempic, also known as semaglutide, is a medication used to treat type 2 diabetes. Recently, it has been in the spotlight due to lawsuits being filed against its manufacturer, Novo Nordisk. These lawsuits claim that Ozempic has been linked to a serious gastrointestinal condition called gastroparesis.

Fortune

Elon Musk and Bernie Sanders say they agree on one thing—cheaper Ozempic

Novo Nordisk is investing $30 billion to expand production, but middlemen are pocketing 74 cents of every dollar it makes in sales.

Roll Call

Novo Nordisk CEO blames PBMs, insurers for Ozempic price tag - Roll Call

Senate HELP Chairman Bernie Sanders launches another salvo in drug pricing war, this one aimed at popular weight loss drugs.

Fortune

Novo Nordisk CEO takes aim at U.S. health system in Ozempic testimony

Novo Nordisk's CEO said the complexities of the U.S. healtchare system prevented access to $1,349 Wegovy.

Roll Call

Analysts say market forces will lower cost of obesity drugs - Roll Call

Hearing on weight loss drug prices will feature CEO of Novo Nordisk and comes after threats to subpoena company executives.

Barchart

Snag This Biotech Stock Before November, Here's Why

With Viking Therapeutics making a splash in the weight-loss drug arena, one analyst is encouraging investors to snap up the stock before a November catalyst.

The Conversation

Ozempic, Wegovy, Rybelsus: Are we losing sight of overall health? Here’s what the science says

The craze for new drugs in the GLP-1 (Glucagon-like peptide 1) and GIP (Gastric inhibitory polypeptide) analogue class, better known under the trade names Ozempic and Wegovy, is remarkable, but it’s not totally unprecedented in the history of pharmaceutical blockbusters.

1 … 14 15 16 17

People

Lars Fruergaard Jørgensen

18 stories

Sally Baker

17 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.